Biomarker-driven management strategies for peripheral T cell lymphoma

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Peripheral T cell lymphomas (PTCL) represent a group of aggressive hematologic malignancies with significant treatment challenges.
• Recent molecular and genomic profiling advances are elucidating PTCL pathogenesis, identifying distinct cell origins and molecular drivers.
• The heterogeneity of PTCL necessitates personalized approaches for effective management.

Purpose of the Study:

• To review the role of molecular biomarkers in advancing the diagnosis, prognosis, and personalized therapy of PTCL subtypes.
• To highlight current and emerging therapeutic strategies targeting specific molecular pathways and the tumor microenvironment in PTCL.

Main Methods:

• Literature review of recent advances in PTCL molecular profiling and clinical trial data.
• Analysis of the impact of molecular biomarkers on diagnostic and therapeutic strategies.
• Examination of novel therapeutic agents and combination strategies in clinical development.

Main Results:

• CD30-targeted therapy (brentuximab vedotin) has improved survival in relapsed and frontline PTCL settings.
• Epigenetic modifying agents (HDAC inhibitors, hypomethylating agents) show clinical efficacy and durability.
• Novel agents targeting intracellular pathways and the tumor microenvironment are under active investigation.

Conclusions:

• Molecular biomarkers are crucial for precision diagnosis and personalized treatment of PTCL.
• Targeted therapies and epigenetic agents represent significant progress in PTCL management.
• Continued research into novel agents and combination strategies holds promise for further improving PTCL patient outcomes.